Dear All,
I am interested on the FDA guidance about End of Phase 2 A (EOP2A)
meetings. Some of you certainly have participated
into the preparation or have attended such meeting (during the pilot phase
or after) and have real life experience. If so, it would be much
apreciated if you could share some of this experience. Thank you in
advance for your replies.
Kind regards,
Pascal Girard
This message and any attachment are confidential and may be privileged or
otherwise protected from disclosure. If you are not the intended recipient, you
must not copy this message or attachment or disclose the contents to any other
person. If you have received this transmission in error, please notify the
sender immediately and delete the message and any attachment from your system.
Merck KGaA, Darmstadt, Germany and any of its subsidiaries do not accept
liability for any omissions or errors in this message which may arise as a
result of E-Mail-transmission or for damages resulting from any unauthorized
changes of the content of this message and any attachment thereto. Merck KGaA,
Darmstadt, Germany and any of its subsidiaries do not guarantee that this
message is free of viruses and does not accept liability for any damages caused
by any virus transmitted therewith.
Click http://disclaimer.merck.de to access the German, French, Spanish and
Portuguese versions of this disclaimer.
EOP2A experience?
Hi Pascal
I'm not sure if you are aware of the recent AAPS webinar on EOP2A conducted
by Joga Gobburu but you may find it useful:
http://mediaserver.aapspharmaceutica.com/meetings/webinars/archives.pdf
Regards
Masoud
Quoted reply history
On 10 August 2010 16:32, <[email protected]> wrote:
>
> Dear All,
>
> I am interested on the FDA guidance about End of Phase 2 A (EOP2A)
> meetings. Some of you certainly have participated
> into the preparation or have attended such meeting (during the pilot phase
> or after) and have real life experience. If so, it would be much apreciated
> if you could share some of this experience. Thank you in advance for your
> replies.
>
> Kind regards,
>
> Pascal Girard
> This message and any attachment are confidential and may be privileged or
> otherwise protected from disclosure. If you are not the intended recipient,
> you must not copy this message or attachment or disclose the contents to any
> other person. If you have received this transmission in error, please notify
> the sender immediately and delete the message and any attachment from your
> system. Merck KGaA, Darmstadt, Germany and any of its subsidiaries do not
> accept liability for any omissions or errors in this message which may arise
> as a result of E-Mail-transmission or for damages resulting from any
> unauthorized changes of the content of this message and any attachment
> thereto. Merck KGaA, Darmstadt, Germany and any of its subsidiaries do not
> guarantee that this message is free of viruses and does not accept liability
> for any damages caused by any virus transmitted therewith.
>
> Click * http://disclaimer.merck.de* to access the German, French, Spanish
> and Portuguese versions of this disclaimer.